Paradigm Biocapital Advisors LP Y M Abs Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,236,346 shares of YMAB stock, worth $36.5 Million. This represents 0.89% of its overall portfolio holdings.
Number of Shares
4,236,346
Previous 4,236,346
-0.0%
Holding current value
$36.5 Million
Previous $18.8 Million
1.8%
% of portfolio
0.89%
Previous 0.96%
Shares
4 transactions
Others Institutions Holding YMAB
# of Institutions
97Shares Held
26MCall Options Held
24KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY3.42MShares$29.4 Million10.09% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$25.3 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$18.9 Million0.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$16.7 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.79MShares$15.4 Million0.05% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $376M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...